June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
3 citations
,
October 2018 in “Journal of cosmetic dermatology” Pentoxifylline alone and combined with triamcinolone acetonide is effective for treating localized alopecia areata, with the combination showing the highest effectiveness.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
November 2025 in “Archives of Dermatological Research” Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.
January 2009 in “Yearbook of Dermatology and Dermatologic Surgery” Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
Baricitinib is more effective than methotrexate for severe alopecia areata.
June 2025 in “Veterinary Sciences” Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
Cetirizine-loaded gel may effectively promote hair growth in alopecia.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
January 2013 in “Journal of Chengdu Medical College” Tolterodine Tartrate effectively treats overactive bladder symptoms.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
9 citations
,
May 2021 in “Molecules” New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.